Wockhardt announces approval of Famotidine (OTC), March 11 2005, Mumbai

Pharmaceutical and biotechnology major Wockhardt Limited said it received US FDA approval for marketing the OTC (over the counter) version of Famotidine, an anti-ulcer drug, in the US market. Wockhardt had earlier received US FDA approval for marketing Famotidine 20 mg and 40 mg tablets, both prescription products. With the approval for Famotidine 10 mg OTC medication, Wockhardt is now present in the entire product range with a combined market size of $135 million. Wockhardt's US subsidiary Wockhardt USA Inc, expects to launch famotidine in the US market next month.

Wockhardt USA is wholly owned subsidiary of Wockhardt Ltd, a leading research-based pharmaceutical and health care Indian company headquartered in India. Through its sales and marketing headquarters in New Jersey, Wockhardt USA is committed to providing safe and affordable generic medicines to its US customers. For information on Wockhardt Group, please visit www.wockhardt.com

Important Disclaimer
The information provided in this website is for general and/or educational purpose only and is not intended to replace consultation with a qualified health care professional. For information on a specific medicine or for answers to your own particular health concerns, you should always consult with your doctor or pharmacist for their professional advice. Wockhardt USA accepts no liability for any damages, including without limitation, direct, indirect, incidental, consequential or punitive damages, arising out of or due to information given or not given in this website. Use of any information contained in this website is subject to your acceptance of Term of Use Agreement and/or our Privacy Policy Statement

For further information, please contact:
Wockhardt USA, Inc.
75 Ronald Reagan Blvd.
Warwick, NY 10990
Phone: (845) 987-1191
Fax: (845) 987-1193
Email: usa@wockhardt.com